Advertisement

Infusion of iodine-based contrast agents into poly(p-dioxanone) as a radiopaque resorbable IVC filter

  • Burapol Singhana
  • Aaron Chen
  • Patrick Slattery
  • Iman K. Yazdi
  • Yang Qiao
  • Ennio Tasciotti
  • Michael Wallace
  • Steven Huang
  • Mitch Eggers
  • Marites P. Melancon
Clinical Applications of Biomaterials
Part of the following topical collections:
  1. Clinical Applications of Biomaterials

Abstract

To determine the feasibility of infusing resorbable inferior vena cava (IVC) filter with iodine-based contrast agents to produce a radiopaque, computed tomography (CT)-visible IVC filter. Infused poly(p-dioxanone) (PPDO) was obtained by incubating PPDO in different concentrations of 4-iodobenzoyl chloride (IBC) and 2,3,5-triiodobenzoic acid (TIBA). Characterizations of infused and nascent PPDO were done using elemental analysis, micro-CT, tensile strength analysis, scanning electron microscopy, and differential scanning calorimetry. Elemental analysis showed percentage loading of 1.07 ± 0.08 for IBC and 0.73 ± 0.01 for TIBA. The iodine loading remained the same within 2 weeks for TIBA but decreased to about 80 % with IBC when subjected to physiological conditions. Micro-CT images showed increased attenuation of the infused PPDO compared with the nascent PPDO. The Hounsfield unit values for infused and nascent sutures were 110 ± 40 and 153 ± 53 for PPDO infused with 2 mg/mL IBC and TIBA, respectively, but only 11.35 ± 2 for nascent PPDO. In contrast the HU for bone was 116 ± 37. Tensile strength analysis showed maximum loads of 1.01 ± 0.43 kg and 10.02 ± 0.54 kg for IBC and TIBA, respectively, and 10.10 ± 0.64 kg for nascent PPDO. Scanning electron microscopy showed that the morphology of the PPDO surface did not change after coating and preliminary cytotoxicity assay showed no killing effect on Hela cells. PPDO infused with a contrast agent is significantly more radiopaque than nascent PPDO on micro-CT imaging. This radiopacity could allow the position and integrity of infused resorbable IVC filter to be monitored while it is in place, thus increasing its safety and efficacy as a medical device.

Keywords

Inferior Vena Cava Hounsfield Unit Triclosan TIBA Inferior Vena Cava Filter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Sarah Bronson and Dawn Chalaire for editing the manuscript. This work was supported in part by the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center, the John S. Dunn Foundation, and The University of Texas MD Anderson Cancer Center’s Cancer Center Support Grant CA016672 from the National Institutes of Health for the small-animal imaging and veterinary pathology core facilities. We would like to thank Kiersten Maldonado, Charles Kingsley, Jorge de la Cerda, and Keith Michel for providing assistance in micro-CT imaging.

References

  1. 1.
    Ni H, Win LL. Retrievable inferior vena cava filters for venous thromboembolism. ISRN Radiol. 2013;. doi: 10.5402/2013/959452.Google Scholar
  2. 2.
    Imberti D, Ageno W, Dentali F, Donadini M, Manfredini R, Gallerani M. Retrievable vena cava filters: a clinical review. J Thromb Thrombolysis. 2012;33:258–66.CrossRefGoogle Scholar
  3. 3.
    Society of Interventional Radiology. IVC filters: Society of Interventional Radiology leads in patient care, safety, research. 2011. http://www.sirweb.org/news/newsPDF/Release_JVIR_IVCF_Nov11_final.pdf. Accessed 30 Apr 2014.
  4. 4.
    The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112:416–22.CrossRefGoogle Scholar
  5. 5.
    Franz RW, Jason DJ, Kaushal JS. Symptomatic inferior vena cava perforation by a retrievable filter: report of two cases and a literature review. Int J Angiol. 2009;18:203–6.CrossRefGoogle Scholar
  6. 6.
    Comerota AJ. Retrievable IVC filters: a decision matrix for appropriate utilization. Perspect Vasc Surg Endovasc Ther. 2006;18:11–7.CrossRefGoogle Scholar
  7. 7.
    Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, Cipolle M, Comerota AJ, Millward SF, Rogers FB, Sacks D, Venbrux AC. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006;17:449–59.CrossRefGoogle Scholar
  8. 8.
    Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, McNally M, Jacoby RC, Link D, Janczyk RJ, Ivascu FA, McCann M, Obeid F, Hoff WS, McQuay N, Tieu BH, Schreiber MA, Nirula R, Brasel K, Dunn JA, Gambrell D, Huckfeldt R, Harper J, Schaffer KB, Tominaga GT, Vinces FY, Sperling D, Hoyt D, Coimbra R, Rosengart MR, Forsythe R, Cothren C, Moore EE, Haut ER, Hayanga AJ, Hird L, White C, Grossman J, Nagy K, Livaudais W, Wood R, Zengerink I, Kortbeek JB. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma. 2007;62:17–25.CrossRefGoogle Scholar
  9. 9.
    Thors A, Muck P. Resorbable inferior vena cava filters: trial in an in vivo porcine model. J Vasc Interv Radiol. 2011;22:330–5.CrossRefGoogle Scholar
  10. 10.
    Eggers M, Reitman CA. In vitro analysis of polymer candidates for the development of absorbable vascular filters. J Vasc Interv Radiol. 2012;23:1023–30.CrossRefGoogle Scholar
  11. 11.
    U.S. Food and Drug Administration. Removing retrievable inferior vena cava filters: FDA safety communication. May 6, 2014. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm. Accessed 30 July 2014.
  12. 12.
    Wever DJ, Veldhuizen AG, Sanders MM, Schakenraad JM, van Horn JR. Cytotoxic, allergic and genotoxic activity of a nickel-titanium alloy. Biomaterials. 1997;18:1115–20.CrossRefGoogle Scholar
  13. 13.
    Blanco MG, Franco L, Puiggali J, Rodriguez-Galan A. Incorporation of triclosan into polydioxanone monofilaments and evaluation of the corresponding release. J Appl Polym Sci. 2009;114:3440–51.CrossRefGoogle Scholar
  14. 14.
    Wang XL, Chen YY, Wang YZ. Synthesis of poly(p-dioxanone) catalyzed by Zn l-lactate under microwave irradiation and its application in ibuprofen delivery. J Biomater Sci Polym Ed. 2010;21:927–36.CrossRefGoogle Scholar
  15. 15.
    Ming XT, Rothenburger S, Nichols MM. In vivo and in vitro antibacterial efficacy of PDS plus (polidioxanone with triclosan) suture. Surg Infect. 2008;9:451–7.CrossRefGoogle Scholar
  16. 16.
    Zurita R, Puiggali J, Rodriguez-Galan A. Triclosan release from infused polyglycolide threads. Macromol Biosci. 2006;6:58–69.CrossRefGoogle Scholar
  17. 17.
    Gan Z, Yu D, Zhong Z, Liang Q, Jing X. Enzymatic degradation of poly(ε-caprolactone)/poly(dl-lactide) blends in phosphate buffer solution. Polymer. 1999;40:2859.CrossRefGoogle Scholar
  18. 18.
    Sabino MA, Gonzalez S, Márquez L, Feijoo J. Study of the hydrolytic degradation of polydioxanone PPDX. Polym Degrad Stabil. 2000;69:209–16.CrossRefGoogle Scholar
  19. 19.
    Luderer F, Begerow I, Schmidt W, et al. Enhanced visualization of biodegradable polymeric vascular scaffolds by incorporation of gold, silver and magnetite nanoparticles. J Biomater Appl. 2013;28:219–31.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Burapol Singhana
    • 1
    • 2
  • Aaron Chen
    • 3
  • Patrick Slattery
    • 4
  • Iman K. Yazdi
    • 5
  • Yang Qiao
    • 1
  • Ennio Tasciotti
    • 5
  • Michael Wallace
    • 1
  • Steven Huang
    • 1
  • Mitch Eggers
    • 6
  • Marites P. Melancon
    • 1
    • 7
  1. 1.Department of Interventional RadiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.The Faculty of Liberal Arts and SciencesNakhon Phanom UniversityNakhon PhanomThailand
  3. 3.The University of Texas Medical School at HoustonHoustonUSA
  4. 4.College of MedicineNortheast Ohio Medical UniversityRootstownUSA
  5. 5.Department of NanomedicineHouston Methodist Research InstituteHoustonUSA
  6. 6.Adient MedicalPearlandUSA
  7. 7.The University of Texas Graduate School of Biomedical Sciences at HoustonHoustonUSA

Personalised recommendations